CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
Healthcare
$1.88 -0.91%
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
52W Low $1.72High $8.21
Volume 4.39M
Average 4.99M
Income Statement
Follow revenue through to earnings.
Revenue
$76.20M
FY 2025 · Annual
-44.8% YoYOperating Income
-$22.36M
FY 2025 · Annual
Net Income
-$17.37M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 114.19M | 111.65M | 77.68M | 83.38M | 68.73M |
| Selling, General & Admin | 39.16M | 42.85M | 30.02M | 29.73M | 29.84M |
| Operating Expenses | 153.35M | 154.5M | 107.7M | 113.11M | 98.57M |
| Depreciation & Amortization | 2.71M | 2.44M | 2.18M | 1.77M | 1.38M |
| EBITDA | (113.16M) | (96.87M) | 5.5M | 33.86M | (15.75M) |
| EBITDA Margin | -303.3% | -182.2% | 5.4% | 24.5% | -20.7% |
| Operating Income | (116.04M) | (101.34M) | (6.48M) | 25M | (22.36M) |
| Operating Margin | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Interest Income | 255K | 1.68M | 9.84M | 7.14M | 5.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 172K | 2.02M | 9.81M | 7.1M | 5.23M |
| Income Before Tax | (115.87M) | (99.32M) | 3.32M | 32.09M | (17.13M) |
| Pre-Tax Margin | -310.5% | -186.8% | 3.3% | 23.2% | -22.5% |
| Income Tax Expense | 0 | 0 | 3.89M | 224K | 238K |
| Net Income | (115.87M) | (99.32M) | (569K) | 31.87M | (17.37M) |
| Net Margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| EPS (Basic) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| EPS (Diluted) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| 64.15M | 65.74M | 73.81M | 84.44M | 137.94M | |
| 64.15M | 65.74M | 73.81M | 84.75M | 137.94M |
CTMX Earnings Waterfall · TTM
NASDAQ:CTMX · Revenue to Net Income
Key Ratios
EPS$-0.36
Gross Margin99.4%
Net Margin-1104.0%
P/E Ratio-125.8
P/S Ratio319.7
Analysis
$35.5M of revenue converted into -$59.1M of net income for the selected period. Gross margin is 99.4% and net margin is -1104.0%, showing how much revenue survives after costs and taxes. EPS is $-0.36, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 28, 2026 | |
| 4/A | 4/A filing | Oct 16, 2026 |
How much revenue does CTMX generate?
CytomX Therapeutics, Inc. (CTMX) reported $76.20M of revenue in fiscal 2025.
Is CTMX profitable?
CytomX Therapeutics, Inc. (CTMX) reported -$17.37M of net income, with a net margin of -22.8%.
Continue the stock analysis
Jump to another research area for this company.